<unk> , sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.<unk>  is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Inebilizumab
Brolucizumab
Risankizumab
Mogamulizumab
Reslizumab
Tildrakizumab
Ixekizumab
Crizanlizumab